Elyxium Wealth LLC Has $5.16 Million Holdings in Amgen Inc. $AMGN

Elyxium Wealth LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 607.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,252 shares of the medical research company’s stock after purchasing an additional 12,237 shares during the period. Elyxium Wealth LLC’s holdings in Amgen were worth $5,161,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in AMGN. High Note Wealth LLC increased its holdings in Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares during the last quarter. Verus Capital Partners LLC lifted its stake in Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares during the last quarter. Destination Wealth Management grew its position in Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares in the last quarter. Finally, Breakwater Capital Group grew its position in Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after acquiring an additional 29 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 0.6%

NASDAQ:AMGN opened at $415.21 on Friday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $421.79. The firm has a market cap of $224.47 billion, a price-to-earnings ratio of 25.81, a P/E/G ratio of 3.88 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company’s 50 day moving average is $370.57 and its 200-day moving average is $358.93.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. Amgen’s payout ratio is currently 62.65%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. TD Cowen raised their price target on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Robert W. Baird upped their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Morgan Stanley increased their target price on shares of Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Guggenheim raised their target price on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a report on Monday. Finally, Canaccord Genuity Group boosted their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $372.39.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.